We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Catalyst Pharmaceuticals (CPRX) This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Catalyst Pharmaceutical (CPRX - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Catalyst Pharmaceutical is a member of our Medical group, which includes 1188 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Catalyst Pharmaceutical is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for CPRX's full-year earnings has moved 4.8% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that CPRX has returned about 90.8% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of -21.1% on a year-to-date basis. As we can see, Catalyst Pharmaceutical is performing better than its sector in the calendar year.
One other Medical stock that has outperformed the sector so far this year is AxoGen (AXGN - Free Report) . The stock is up 24.2% year-to-date.
The consensus estimate for AxoGen's current year EPS has increased 6.8% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Catalyst Pharmaceutical belongs to the Medical - Drugs industry, a group that includes 218 individual stocks and currently sits at #86 in the Zacks Industry Rank. On average, stocks in this group have lost 27.9% this year, meaning that CPRX is performing better in terms of year-to-date returns.
On the other hand, AxoGen belongs to the Medical - Instruments industry. This 103-stock industry is currently ranked #145. The industry has moved -34.2% year to date.
Catalyst Pharmaceutical and AxoGen could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging Catalyst Pharmaceuticals (CPRX) This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Catalyst Pharmaceutical (CPRX - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Catalyst Pharmaceutical is a member of our Medical group, which includes 1188 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Catalyst Pharmaceutical is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for CPRX's full-year earnings has moved 4.8% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that CPRX has returned about 90.8% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of -21.1% on a year-to-date basis. As we can see, Catalyst Pharmaceutical is performing better than its sector in the calendar year.
One other Medical stock that has outperformed the sector so far this year is AxoGen (AXGN - Free Report) . The stock is up 24.2% year-to-date.
The consensus estimate for AxoGen's current year EPS has increased 6.8% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Catalyst Pharmaceutical belongs to the Medical - Drugs industry, a group that includes 218 individual stocks and currently sits at #86 in the Zacks Industry Rank. On average, stocks in this group have lost 27.9% this year, meaning that CPRX is performing better in terms of year-to-date returns.
On the other hand, AxoGen belongs to the Medical - Instruments industry. This 103-stock industry is currently ranked #145. The industry has moved -34.2% year to date.
Catalyst Pharmaceutical and AxoGen could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.